카르바페넴 내성 장내세균속균종 감염증 : 시장 인사이트, 역학, 시장 예측(-2034년)

Carbapenem-resistant Enterobacteriaceae Infection - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,795,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 17,693,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 23,590,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 35,386,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 주요 7개국의 카르바페넴 내성 장내세균속균종 감염증 시장을 조사했으며, 질환 배경·개요, 역학, 치료와 관리의 개요, 시장 성장 촉진요인과 장벽, 미충족 요구, 출시약 및 파이프라인약의 개요, 주요 국가 시장 규모 추이·예측, 경쟁 구도 등을 정리하고, 최적의 기회를 발굴하고, 시장의 잠재력을 평가합니다.

대상 지역

• 미국
• 유럽 5개국(독일·프랑스·이탈리아·스페인·영국)
• 일본

조사 기간 : 2020-2034년

리포트 하이라이트

• 카르바페넴 내성 장내세균속균종 감염증 시장은 질환에 대한 인식의 향상과 의료 지출의 세계 증가에 의해 향후 수년간 변화를 보일 것으로 생각되고 있습니다.
• 기업 및 연구기관은 카르바페넴 내성 장내세균속균종 감염증의 연구개발에 영향을 미칠 가능성이 있는 과제를 분석하고 기회를 모색하기 위해 노력하고 있습니다. 개발중인 치료제는 병태를 치료/개선하기 위한 신규 어프로치에 초점을 맞추고 있습니다.
• 대기업은 카르바페넴 내성 장내세균속균종 감염증 치료제의 개발에 참여하고 있습니다. 새로운 치료제의 출시는 시장에 큰 영향을 미칠 전망입니다.
• 카르바페넴 내성 장내세균속균종 감염증 신규 치료제의 개발에는 질환 병태의 보다 깊은 이해가 필요합니다.
• 당사의 개발 단계별(제III상 및 제II상) 파이프라인 어셋에 관한 상세한 분석, 다양한 신규 동향, 상세한 임상 개요, 주요 크로스 경쟁, 발매일, 제품 개발 활동을 포함한 파이프라인약의 비교 분석은 연구개발 활동의 전체적인 시나리오를 식별하는 것으로 치료 포트폴리오에 관한 의사결정 프로세스에서 클라이언트를 지원합니다.

목차

제1장 주요 인사이트

제2장 카르바페넴 내성 장내세균속균종 감염증 : 개요

제3장 카르바페넴 내성 장내세균속균종 감염증 : 경쟁 분석

제4장 카르바페넴 내성 장내세균속균종 감염증 : 시장 개요

• 전체 시장 점유율(%) 분포 : 2020년
• 전체 시장 점유율(%) 분포 : 2034년

제5장 카르바페넴 내성 장내세균속균종 감염증 : 질환 배경·개요

• 징후와 증상
• 병태생리
• 위험인자
• 진단

제6장 환자 여정

제7장 카르바페넴 내성 장내세균속균종 감염증 : 역학·환자 인구

• 역학 : 주요 조사 결과
• 전제·근거 : 주요 7개국
• 역학 시나리오 : 주요 7개국
  • 주요 7개국 카르바페넴 내성 장내세균속균종 감염증 역학 시나리오 : 2020-2034년
• 역학 : 미국
• 역학 : 유럽 5개국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 역학 : 일본

제8장 치료 알고리즘·현재 치료제·의료 행위

• 카르바페넴 내성 장내세균속균종 감염증 치료와 관리
• 카르바페넴 내성 장내세균속균종 감염증 치료 알고리즘

제9장 미충족 요구

제10장 카르바페넴 내성 장내세균속균종 감염증 치료의 주요 엔드포인트

제11장 출시 제품

• 주요 7개국의 출시 제품 리스트
• 의약품명·기업명
  • 제품 설명
  • 규제 마일스톤
  • 기타 개발 활동
  • 중요 임상시험
  • 주요 임상시험의 개요

제12장 신규 치료제

• 주요 크로스 경쟁
• 의약품명·기업명
  • 제품 설명
  • 기타 개발 활동
  • 임상 개발
  • 안전성과 유효성
  • 제품 개요

제13장 카르바페넴 내성 장내세균속균종 감염증 : 주요 7개국 시장 분석

• 주요 조사 결과
• 주요 7개국 시장 규모
• 주요 7개국 시장 규모 : 치료제별

제14장 속성 분석

제15장 주요 7개국 : 시장 전망

• 미국 : 시장 규모
• 유럽 5개국 : 시장 규모·전망
• 독일
• 프랑스
• 이탈리아
• 스페인
• 영국
• 일본 시장의 전망

제16장 카르바페넴 내성 장내세균속균종 감염증 : 액세스와 상환 개요

제17장 KOL의 견해

제18장 시장 성장 촉진요인

제19장 시장의 장벽

제20장 부록

제21장 DelveInsight의 능력

제22장 면책사항

제23장 DelveInsight 소개

KSA

영문 목차

영문목차

DelveInsight's "Carbapenem-resistant Enterobacteriaceae Infection - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Carbapenem-resistant Enterobacteriaceae Infection, historical and forecasted epidemiology as well as the Carbapenem-resistant Enterobacteriaceae Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Carbapenem-resistant Enterobacteriaceae Infection market report provides current treatment practices, emerging drugs, Carbapenem-resistant Enterobacteriaceae Infection market share of the individual therapies, current and forecasted Carbapenem-resistant Enterobacteriaceae Infection market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Carbapenem-resistant Enterobacteriaceae Infection treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Carbapenem-resistant Enterobacteriaceae Infection Disease Understanding and Treatment Algorithm

The DelveInsight Carbapenem-resistant Enterobacteriaceae Infection market report gives a thorough understanding of the Carbapenem-resistant Enterobacteriaceae Infection by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Carbapenem-resistant Enterobacteriaceae Infection.

Treatment

It covers the details of conventional and current medical therapies available in the Carbapenem-resistant Enterobacteriaceae Infection market for the treatment of the condition. It also provides Carbapenem-resistant Enterobacteriaceae Infection treatment algorithms and guidelines in the United States, Europe, and Japan.

Carbapenem-resistant Enterobacteriaceae Infection Epidemiology

The Carbapenem-resistant Enterobacteriaceae Infection epidemiology division provide insights about historical and current Carbapenem-resistant Enterobacteriaceae Infection patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Carbapenem-resistant Enterobacteriaceae Infection epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Carbapenem-resistant Enterobacteriaceae Infection Epidemiology

The epidemiology segment also provides the Carbapenem-resistant Enterobacteriaceae Infection epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Carbapenem-resistant Enterobacteriaceae Infection Drug Chapters

Drug chapter segment of the Carbapenem-resistant Enterobacteriaceae Infection report encloses the detailed analysis of Carbapenem-resistant Enterobacteriaceae Infection marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Carbapenem-resistant Enterobacteriaceae Infection clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Carbapenem-resistant Enterobacteriaceae Infection treatment.

Carbapenem-resistant Enterobacteriaceae Infection Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Carbapenem-resistant Enterobacteriaceae Infection treatment.

Carbapenem-resistant Enterobacteriaceae Infection Market Outlook

The Carbapenem-resistant Enterobacteriaceae Infection market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Carbapenem-resistant Enterobacteriaceae Infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Carbapenem-resistant Enterobacteriaceae Infection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Carbapenem-resistant Enterobacteriaceae Infection market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Carbapenem-resistant Enterobacteriaceae Infection market in 7MM.

The United States Market Outlook

This section provides the total Carbapenem-resistant Enterobacteriaceae Infection market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Carbapenem-resistant Enterobacteriaceae Infection market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Carbapenem-resistant Enterobacteriaceae Infection market size and market size by therapies in Japan is also mentioned.

Carbapenem-resistant Enterobacteriaceae Infection Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Carbapenem-resistant Enterobacteriaceae Infection market or expected to get launched in the market during the study period 2020-2034. The analysis covers Carbapenem-resistant Enterobacteriaceae Infection market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Carbapenem-resistant Enterobacteriaceae Infection Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Carbapenem-resistant Enterobacteriaceae Infection key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Carbapenem-resistant Enterobacteriaceae Infection emerging therapies.

Reimbursement Scenario in Carbapenem-resistant Enterobacteriaceae Infection

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Carbapenem-resistant Enterobacteriaceae Infection domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Carbapenem-resistant Enterobacteriaceae Infection market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Carbapenem-resistant Enterobacteriaceae Infection Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Carbapenem-resistant Enterobacteriaceae Infection, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Carbapenem-resistant Enterobacteriaceae Infection epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Carbapenem-resistant Enterobacteriaceae Infection are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Carbapenem-resistant Enterobacteriaceae Infection market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Carbapenem-resistant Enterobacteriaceae Infection market

Report Highlights:

• In the coming years, Carbapenem-resistant Enterobacteriaceae Infection market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Carbapenem-resistant Enterobacteriaceae Infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Carbapenem-resistant Enterobacteriaceae Infection. Launch of emerging therapies will significantly impact the Carbapenem-resistant Enterobacteriaceae Infection market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Carbapenem-resistant Enterobacteriaceae Infection
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Carbapenem-resistant Enterobacteriaceae Infection Report Insights

• Patient Population
• Therapeutic Approaches
• Carbapenem-resistant Enterobacteriaceae Infection Pipeline Analysis
• Carbapenem-resistant Enterobacteriaceae Infection Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Carbapenem-resistant Enterobacteriaceae Infection Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Carbapenem-resistant Enterobacteriaceae Infection Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Carbapenem-resistant Enterobacteriaceae Infection Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Carbapenem-resistant Enterobacteriaceae Infection market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Carbapenem-resistant Enterobacteriaceae Infection total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Carbapenem-resistant Enterobacteriaceae Infection market size during the forecast period (2024-2034)?
• At what CAGR, the Carbapenem-resistant Enterobacteriaceae Infection market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Carbapenem-resistant Enterobacteriaceae Infection market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Carbapenem-resistant Enterobacteriaceae Infection market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Carbapenem-resistant Enterobacteriaceae Infection?
• What is the historical Carbapenem-resistant Enterobacteriaceae Infection patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Carbapenem-resistant Enterobacteriaceae Infection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Carbapenem-resistant Enterobacteriaceae Infection?
• Out of all 7MM countries, which country would have the highest prevalent population of Carbapenem-resistant Enterobacteriaceae Infection during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Carbapenem-resistant Enterobacteriaceae Infection treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Carbapenem-resistant Enterobacteriaceae Infection in the USA, Europe, and Japan?
• What are the Carbapenem-resistant Enterobacteriaceae Infection marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Carbapenem-resistant Enterobacteriaceae Infection?
• How many therapies are developed by each company for Carbapenem-resistant Enterobacteriaceae Infection treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Carbapenem-resistant Enterobacteriaceae Infection treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Carbapenem-resistant Enterobacteriaceae Infection therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Carbapenem-resistant Enterobacteriaceae Infection and their status?
• What are the key designations that have been granted for the emerging therapies for Carbapenem-resistant Enterobacteriaceae Infection?
• What are the global historical and forecasted market of Carbapenem-resistant Enterobacteriaceae Infection?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Carbapenem-resistant Enterobacteriaceae Infection market
• To understand the future market competition in the Carbapenem-resistant Enterobacteriaceae Infection market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Carbapenem-resistant Enterobacteriaceae Infection in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Carbapenem-resistant Enterobacteriaceae Infection market
• To understand the future market competition in the Carbapenem-resistant Enterobacteriaceae Infection market

Table of Contents

1. Key Insights

2. Executive Summary of Carbapenem-resistant Enterobacteriaceae Infection

3. Competitive Intelligence Analysis for Carbapenem-resistant Enterobacteriaceae Infection

4. Carbapenem-resistant Enterobacteriaceae Infection: Market Overview at a Glance

• 4.1. Carbapenem-resistant Enterobacteriaceae Infection Total Market Share (%) Distribution in 2020
• 4.2. Carbapenem-resistant Enterobacteriaceae Infection Total Market Share (%) Distribution in 2034

5. Carbapenem-resistant Enterobacteriaceae Infection: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Carbapenem-resistant Enterobacteriaceae Infection Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Carbapenem-resistant Enterobacteriaceae Infection Treatment and Management
• 8.2. Carbapenem-resistant Enterobacteriaceae Infection Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Carbapenem-resistant Enterobacteriaceae Infection Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Carbapenem-resistant Enterobacteriaceae Infection: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Carbapenem-resistant Enterobacteriaceae Infection Market Size in 7MM
• 13.3. Carbapenem-resistant Enterobacteriaceae Infection Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Carbapenem-resistant Enterobacteriaceae Infection Total Market Size in the United States
  • 15.1.2. Carbapenem-resistant Enterobacteriaceae Infection Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Carbapenem-resistant Enterobacteriaceae Infection Total Market Size in Germany
  • 15.3.2. Carbapenem-resistant Enterobacteriaceae Infection Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Carbapenem-resistant Enterobacteriaceae Infection Total Market Size in France
  • 15.4.2. Carbapenem-resistant Enterobacteriaceae Infection Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Carbapenem-resistant Enterobacteriaceae Infection Total Market Size in Italy
  • 15.5.2. Carbapenem-resistant Enterobacteriaceae Infection Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Carbapenem-resistant Enterobacteriaceae Infection Total Market Size in Spain
  • 15.6.2. Carbapenem-resistant Enterobacteriaceae Infection Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Carbapenem-resistant Enterobacteriaceae Infection Total Market Size in the United Kingdom
  • 15.7.2. Carbapenem-resistant Enterobacteriaceae Infection Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Carbapenem-resistant Enterobacteriaceae Infection Total Market Size in Japan
  • 15.8.3. Carbapenem-resistant Enterobacteriaceae Infection Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Carbapenem-resistant Enterobacteriaceae Infection

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

관련자료